Skip to main content
Equibles
BSX logo

BSX · Boston Scientific Corp · Metrics

Track BSX — free

Use BSX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BSX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$45.85 -0.16 (-0.35%)
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$66.22B
Shares
1.45B
Volume · Oct 23 8.79M Avg daily vol (3M) 19.49M

BSX metrics

113 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$45.69
Market cap
$66.22B

Price action

20 metrics
Price change (1W)
+4.2%
Price change (30D)
+2.4%
Price change (3M)
+5.6%
Price change (6M)
-30.0%
Price change (YTD)
-51.7%
Price change (1Y)
-55.7%
Trailing year
Price change (5Y)
+2.6%
52-week high
$104.98
52-week low
$41.58
Change from 52-week high
-56.2%
Change from 52-week low
+10.7%
Annualized volatility
38.5%
Annualized volatility (3M)
34.1%
Beta
0.2
RSI (14D)
59.2
Price vs SMA 50
+0.8%
Price vs SMA 200
-20.8%
Avg volume (3M)
19.58M
Relative volume
0.8
Average dollar volume
$903.04M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
1.45B

Valuation

12 metrics
P / E (TTM)
18.6
Trailing earnings · reciprocal yield 5.4%
PEG ratio
1.2
EV / revenue
3.8×
reciprocal yield 26.7%
EV / EBITDA
14.2×
reciprocal yield 7.1%
EV / EBIT
19.0×
reciprocal yield 5.3%
P / sales
3.2×
reciprocal yield 31.5%
P / book
2.7
reciprocal yield 37.4%
FCF yield
5.4%
TTM · current market cap
Buyback yield
—
P / FCF
18.4
reciprocal yield 5.4%
P / operating cash flow
14.7
reciprocal yield 6.8%
Earnings yield
5.5%

Historical valuation

8 metrics
P / E historical average (3Y)
58.3×
reciprocal yield 1.7%
P / E historical average (5Y)
68.6×
reciprocal yield 1.5%
EV / revenue historical average (3Y)
7.3×
reciprocal yield 13.8%
EV / revenue historical average (5Y)
6.7×
reciprocal yield 14.9%
EV / EBIT historical average (3Y)
44.1×
reciprocal yield 2.3%
EV / EBIT historical average (5Y)
51.6×
reciprocal yield 1.9%
EV / EBITDA historical average (3Y)
29.3×
reciprocal yield 3.4%
EV / EBITDA historical average (5Y)
30.0×
reciprocal yield 3.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-28
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
69.9%
Operating margin
19.8%
Trailing 12 months
Net margin
17.5%
Gross profit (TTM)
$14.68B
Operating profit (TTM)
$4.15B
Net income (TTM)
$3.67B
Trailing 12 months
Diluted EPS (TTM)
$2.47
FCF margin
17.3%
Effective tax rate
5.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$14.09
Gross profit per diluted share (TTM)
$9.85
Operating profit per diluted share (TTM)
$2.79
EBITDA per diluted share (TTM)
$3.74
Net income per diluted share (TTM)
$2.46
Operating cash flow per diluted share (TTM)
$3.04
Free cash flow per diluted share (TTM)
$2.44
Capital expenditures per diluted share (TTM)
$0.61
R&D per diluted share (TTM)
$1.44
Stock compensation per diluted share (TTM)
$0.21
Book value per share
$9.95

Growth

11 metrics
Revenue growth YoY
+7.5%
Year over year
Net income growth YoY
+13.8%
Revenue (TTM)
$21.00B
Trailing 12 months
EPS growth YoY
+15.1%
Shares change YoY
-1.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+16.5%
Revenue CAGR (5Y)
+15.2%
EPS CAGR (3Y)
+62.8%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+57.4%
FCF CAGR (5Y)
+26.4%

Quality

14 metrics
Return on equity
14.7%
Return on assets
8.1%
Debt / equity
0.5
Current ratio
1.2
EBITDA (TTM)
$5.57B
Free cash flow (TTM)
$3.62B
Quick ratio
0.7
Interest coverage
11.4
Net debt / EBITDA
2.2
Return on invested capital
10.7%
Trailing 12 months
Net cash
−$12.09B
Latest balance sheet
Cash & equivalents
$539.00M
Total assets
$45.22B
Total debt
$12.62B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.53B
Capital expenditures (TTM)
$904.00M
R&D (TTM)
$2.15B
SG&A (TTM)
$7.16B
Stock compensation (TTM)
$320.00M
R&D / revenue
10.3%
Stock compensation / revenue
1.5%

Ownership (13F)

9 metrics
13F filers
1,497
13F filer change QoQ
-194
Institutional ownership
95.7%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
18.8%
Private-fund adviser ownership
15.4%
Active holders' share change QoQ
-2.7%
Holder tenure
18.5
Price vs estimated holder cost
-41.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.5%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
$9.49M
Insider-sentiment score
92 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 885725 CUSIP 101137107 13F (30d) 333 filings 315 filers Visit website Investor relations